ZEB2 and colorectal cancer: In addition, colorectal cancer patients (TCGA, Provisional) whose tumors expressed higher levels of ZEB2 (Z > 1.75) or Sp1 (Z > 1.75) had a significantly worse overall survival than patients with lower levels of ZEB2 (Z ≤ 1.75) or Sp1 (Z ≤ 1.75) in their tumors (n = 382, P = 0.0418 and P = 0.0359 for ZEB2 and Sp1, respectively) (Figure 7B).